Faculty of Pharmacy, University of Montreal, PO Box 6128, Downtown Station, Montreal, QC, Canada, H3C 3J7.
J Control Release. 2012 Jul 20;161(2):152-63. doi: 10.1016/j.jconrel.2011.09.098. Epub 2011 Oct 6.
Recent advances in chemistry and material sciences have witnessed the emergence of an increasing number of novel and complex nanosized carriers for the delivery of drugs and imaging agents. Nevertheless, this raise in complexity does not necessarily offer more efficient systems. The lack of performance experienced by several colloidal drug carriers during the preclinical and clinical development processes can be explained by inadequate pharmacokinetic/biodistribution profiles and/or unacceptable toxicities. A comprehensive understanding of the body characteristics is necessary to predict and prevent these problems from the early stages of nanomaterial conception. In this manuscript, we review and discuss the anatomical and physiological elements which must be taken into account when designing new carriers for delivery or imaging purposes. This article gives a general overview of the main organs involved in the elimination of nanosized materials and briefly summarizes the knowledge acquired over more than 30 years of research and development in the field of drug targeting.
近年来,化学和材料科学的发展见证了越来越多新型复杂的纳米载体的出现,这些载体可用于药物和成像剂的递送。然而,这种复杂性的增加并不一定能带来更有效的系统。在临床前和临床开发过程中,几种胶体药物载体的性能不佳,可以用药代动力学/生物分布特征不佳和/或不可接受的毒性来解释。为了预测并预防这些问题在纳米材料概念的早期阶段出现,需要全面了解机体特征。在本文中,我们综述并讨论了在设计用于递药或成像的新型载体时需要考虑的解剖学和生理学因素。本文概述了参与纳米材料清除的主要器官,并简要总结了 30 多年来药物靶向领域研究和开发中获得的知识。